2009 Neurotrophic Factors Gordon Research Conference

2009年神经营养因子戈登研究会议

基本信息

  • 批准号:
    7672016
  • 负责人:
  • 金额:
    $ 2.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-04-01 至 2010-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We ask for partial support for the 2009 Neurotrophic Factors Gordon Research Conference. The conference will be held in June of 2009, from June 21st through 26th, at Salve Regina University in Newport, Rhode Island. This conference, held every other year, is viewed as the most important meeting for conveying the most significant discoveries in the neurotrophic factor field. It attracts virtually all of the leading scientists studying neuronal growth factors, their mechanisms of action and their roles in development, plasticity and diseases of the nervous system. Moreover, in recent years it has been attended by a significant number of clinicians and scientists in the related fields of developmental neuroscience, and neurological and mental health disorders and by industry representatives whose companies engage in research in neurological and mental health disorders. Over the years, many of the major breakthroughs in the field have been showcased at this meeting. The Conference has played a catalytic role in building the neuroscience community by bringing together both young and established investigators with diverse interests in neurotrophic factors and with expertise in molecular biology, cell biology, signal transduction, synaptic transmission, development, behavior and disease. The goals of the 2009 Conference are: 1. To communicate and disseminate new findings about known and novel functions of neurotrophic factors, including the impact of such factors in the biology of a variety of different types of stem cells and their potential therapeutic uses. 2. To explore recent advances regarding the synthesis, secretion, signaling mechanisms of neurotrophic factors and their actions in development, plasticity, and the maintenance of neuronal circuits in the young, aged, and diseased nervous system. 3. To disseminate knowledge about the emerging methodologies that are for the first time making it possible to examine in "real-time" the trafficking, signaling and actions of neurotrophic factors. 4. To increase knowledge within the community of the new tools now available that allow scientists to more effectively pursue neurotrophic factor actions in mental and neurological disorders. 5. To increase collaboration between research groups using molecular, genetic, and cell biological approaches with neurologists as well as industry scientists interested in the use of neurotrophic factors for therapeutic purposes. 6. To provide a venue for discussion of new ideas and to facilitate the exchange of reagents and unpublished information. 7. To provide an atmosphere for students, postdoctoral fellows and new faculty to meet and interact with senior scientists studying growth factor biology. 8. To highlight the contributions to our field being made by underrepresented individuals, especially women and minorities. The Conference will enhance communication between scientists working in diverse disciplines to increase their ability to understand neurotrophic factors and to deduce how exploiting their actions may allow us to enhance the lives of individuals with disorders of the nervous system. PUBLIC HEALTH RELEVANCE: The public health relevance of the Conference is its ability to accelerate the transmission of knowledge from fundamental neuroscience to the benefit of patients that suffer with a variety of disorders - Alzheimer's disease, Down syndrome, Parkinson's disease, Huntington's disease, depression, obesity, epilepsy, stroke, and peripheral neuropathies, including those that complicate diabetes and other chronic medical disorders. As such, it fills an important gap in creating and sustaining research with enormous potential benefit to the health and well being of America and the rest of the world. Indeed, we expect this conference to catalyze many new collaborations that address questions important to understanding and treating neurological and mental disorders.
描述(由申请人提供):我们请求为 2009 年神经营养因子戈登研究会议提供部分支持。该会议将于 2009 年 6 月(6 月 21 日至 26 日)在罗德岛州纽波特的 Salve Regina 大学举行。该会议每隔一年举行一次,被视为传达神经营养因子领域最重要发现的最重要会议。它吸引了几乎所有研究神经元生长因子、其作用机制及其在神经系统发育、可塑性和疾病中的作用的顶尖科学家。此外,近年来,发育神经科学、神经和精神健康障碍相关领域的大量临床医生和科学家以及从事神经和精神健康障碍研究的公司的行业代表参加了此次会议。多年来,该领域的许多重大突破都在这次会议上得到展示。该会议汇集了对神经营养因子具有不同兴趣以及在分子生物学、细胞生物学、信号转导、突触传递、发育、行为和疾病方面具有专业知识的年轻和成熟的研究人员,在建立神经科学界方面发挥了催化作用。 2009年会议的目标是: 1. 交流和传播有关神经营养因子已知和新功能的新发现,包括这些因子对各种不同类型干细胞生物学的影响及其潜在的治疗用途。 2. 探讨神经营养因子的合成、分泌、信号传导机制及其在年轻、老年和患病神经系统的发育、可塑性和神经回路维持中的作用的最新进展。 3. 传播有关新兴方法的知识,这些方法首次使“实时”检查神经营养因子的运输、信号传导和作用成为可能。 4. 增加社区内对现有新工具的了解,使科学家能够更有效地研究神经营养因子在精神和神经系统疾病中的作用。 5. 加强使用分子、遗传和细胞生物学方法的研究小组与神经学家以及对神经营养因子用于治疗目的感兴趣的行业科学家之间的合作。 6. 提供讨论新想法的场所并促进试剂和未发表信息的交流。 7. 为学生、博士后和新教师提供与研究生长因子生物学的资深科学家会面和互动的氛围。 8. 强调代表性不足的个人,特别是妇女和少数群体对我们领域做出的贡献。会议将加强不同学科科学家之间的交流,以提高他们理解神经营养因子的能力,并推断出利用他们的行为如何可以让我们改善神经系统疾病患者的生活。 公共健康相关性:会议与公共健康的相关性在于它能够加速基础神经科学知识的传播,造福患有各种疾病的患者,包括阿尔茨海默病、唐氏综合症、帕金森病、亨廷顿病、抑郁症、肥胖、癫痫、中风和周围神经病变,包括那些使糖尿病和其他慢性疾病复杂化的疾病。因此,它填补了创建和维持研究方面的一个重要空白,对美国和世界其他地区的健康和福祉具有巨大的潜在好处。事实上,我们期望这次会议能够促进许多新的合作,解决对理解和治疗神经和精神疾病重要的问题。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William C Mobley其他文献

William C Mobley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William C Mobley', 18)}}的其他基金

Antisense Oligonucleotides targeting APP to prevent neurodegeneration in models of Down Syndrome and Alzheimer's disease
靶向 APP 的反义寡核苷酸可预防唐氏综合症和阿尔茨海默病模型中的神经变性
  • 批准号:
    10554249
  • 财政年份:
    2019
  • 资助金额:
    $ 2.7万
  • 项目类别:
Antisense Oligonucleotides targeting APP to prevent neurodegeneration in models of Down Syndrome and Alzheimer's disease
靶向 APP 的反义寡核苷酸可预防唐氏综合症和阿尔茨海默病模型中的神经变性
  • 批准号:
    10543710
  • 财政年份:
    2019
  • 资助金额:
    $ 2.7万
  • 项目类别:
Antisense Oligonucleotides targeting APP to prevent neurodegeneration in models of Down Syndrome and Alzheimer's disease
靶向 APP 的反义寡核苷酸可预防唐氏综合症和阿尔茨海默病模型中的神经变性
  • 批准号:
    9905472
  • 财政年份:
    2019
  • 资助金额:
    $ 2.7万
  • 项目类别:
Antisense Oligonucleotides targeting APP to prevent neurodegeneration in models of Down Syndrome and Alzheimer's disease
靶向 APP 的反义寡核苷酸可预防唐氏综合症和阿尔茨海默病模型中的神经变性
  • 批准号:
    10334410
  • 财政年份:
    2019
  • 资助金额:
    $ 2.7万
  • 项目类别:
Antisense Oligonucleotides targeting APP to prevent neurodegeneration in models of Down Syndrome and Alzheimer's disease
靶向 APP 的反义寡核苷酸可预防唐氏综合症和阿尔茨海默病模型中的神经变性
  • 批准号:
    10092057
  • 财政年份:
    2019
  • 资助金额:
    $ 2.7万
  • 项目类别:
Treating with Gamma-Secretase Modulators to Prevent Neurodegeneration in Mouse Models of Down Syndrome and Alzheimer Disease
使用γ-分泌酶调节剂治疗以预防唐氏综合症和阿尔茨海默病小鼠模型的神经退行性变
  • 批准号:
    10338158
  • 财政年份:
    2018
  • 资助金额:
    $ 2.7万
  • 项目类别:
Alzheimer's Disease Cooperative Study
阿尔茨海默病合作研究
  • 批准号:
    9021933
  • 财政年份:
    2015
  • 资助金额:
    $ 2.7万
  • 项目类别:
NEURONAL AXONS (AXONS FROM DRG NEURONS)
神经元轴突(来自 DRG 神经元的轴突)
  • 批准号:
    8361107
  • 财政年份:
    2011
  • 资助金额:
    $ 2.7万
  • 项目类别:
Genetic Basis of Failed Cognition in Young and Aged Mouse Models of Trisomy 21
21 三体年轻和老年小鼠模型认知失败的遗传基础
  • 批准号:
    8145581
  • 财政年份:
    2010
  • 资助金额:
    $ 2.7万
  • 项目类别:
Genetic Basis of Failed Cognition in Young and Aged Mouse Models of Trisomy 21
21 三体年轻和老年小鼠模型认知失败的遗传基础
  • 批准号:
    8725237
  • 财政年份:
    2010
  • 资助金额:
    $ 2.7万
  • 项目类别:

相似国自然基金

基于神经退行性疾病前瞻性队列的新烟碱类杀虫剂暴露对阿尔茨海默病的影响及作用机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    53 万元
  • 项目类别:
    面上项目
基于miRNA介导ceRNA网络调控作用的防治阿尔茨海默病及认知障碍相关疾病药物的发现研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
LMTK1调控核内体转运介导阿尔茨海默病神经元Reserve机制研究
  • 批准号:
    81903703
  • 批准年份:
    2019
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
基于自组装多肽纳米探针检测蛋白标志物用于阿尔茨海默病精准诊断的研究
  • 批准号:
    31900984
  • 批准年份:
    2019
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目
靶向干预CD33/Aβ相互作用改善小胶质细胞功能延缓AD病理进程
  • 批准号:
    81901072
  • 批准年份:
    2019
  • 资助金额:
    20.5 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Uncovering Mechanisms of Racial Inequalities in ADRD: Psychosocial Risk and Resilience Factors for White Matter Integrity
揭示 ADRD 中种族不平等的机制:心理社会风险和白质完整性的弹性因素
  • 批准号:
    10676358
  • 财政年份:
    2024
  • 资助金额:
    $ 2.7万
  • 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
  • 批准号:
    10749539
  • 财政年份:
    2024
  • 资助金额:
    $ 2.7万
  • 项目类别:
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
  • 批准号:
    10462257
  • 财政年份:
    2023
  • 资助金额:
    $ 2.7万
  • 项目类别:
Core D: Integrated Computational Analysis Core
核心D:综合计算分析核心
  • 批准号:
    10555896
  • 财政年份:
    2023
  • 资助金额:
    $ 2.7万
  • 项目类别:
Core B: B-HEARD Core
核心 B:B-HEARD 核心
  • 批准号:
    10555691
  • 财政年份:
    2023
  • 资助金额:
    $ 2.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了